Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03496571 · ClinicalTrials.gov registry record · Phase 2
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
A Phase 2 study, sponsored by Allakos.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT03496571 is a Phase 2 study that has completed, run by Allakos. The registered enrollment target is 65 participants.
The verdict
NCT03496571, a Phase 2 study, has completed, sponsored by Allakos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses. It is hypothesized that AK002 is more effective than placebo control (alternative hypothesis) in reducing the number of eosinophils per high power field (HPF) in gastric and/or duodenal biopsies before and after receiving AK002 or placebo versus no difference between AK002 and placebo control (null hypothesis).
Interventions
- OTHER Placebo
- DRUG AK002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2019-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03496571
The ClinicalTrials.gov registry entry for NCT03496571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allakos, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03496571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03496571 about?
NCT03496571 is a clinical study titled "A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis". This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses. It is hypothesized that AK002 is more effective than placebo control (alternative hypothesis) in reducing the number of eosinophils per high power field (HPF) in gastric a...
What is the current status of trial NCT03496571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2018-07-18. Estimated completion is 2019-06-24.
What interventions are being tested in trial NCT03496571?
The interventions under investigation include: Placebo (OTHER), AK002 (DRUG).
Who is sponsoring clinical trial NCT03496571?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.